Bromide in Patients with SCN1A-Mutations Manifesting as Dravet Syndrome
Bromide in Patients with SCN1A-Mutations Manifesting as Dravet Syndrome
复制标题
DOI：
10.1055/s-0032-1307454
复制
发表时间：
2012-02-01
期刊：
影响因子：
1.4
通讯作者：
Kluger, Gerhard Josef
中科院分区：
文献类型：
--
作者：
Lotte, Jan;Haberlandt, Edda;Kluger, Gerhard Josef
我们报告了一项回顾性分析，对32例接受溴化治疗的伴有scn1a突变的Dravet综合征患者进行溴化治疗。溴化治疗3个月后，26例患者（81%）表现出相关改善，18例（12例）患者（分别为56%和37%）癫痫发作频率降低50%（75%）。12个月后，我们观察到15(9)例患者（分别为47%和28%）的>减少50%（>减少75%）。18例患者（56%）出现长期缓解。5/32例患者不良反应以轻度或中度为主，导致终止治疗；无加重报告。我们得出结论，溴化物对患有Dravet综合征的scn1a突变患者有希望。
We report a retrospective analysis of bromide therapy in 32 patients suffering from Dravet syndrome with SCN1A-mutations who received bromide. After 3 months of bromide treatment, 26 patients (81%) showed a relevant improvement with a reduction of seizure frequency by >50% (>75%) in 18 (12) patients (56 and 37%, respectively). After 12 months, we observed a reduction of >50% (>75%) in 15 (9) patients (47 and 28%, respectively). Long-term response was noted in 18 patients (56%). Adverse reactions were mainly mild or moderate leading to treatment termination in 5/32 patients; no aggravation was reported. We conclude that bromide holds promise in patients with SCN1A-mutations suffering from Dravet syndrome.